Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation

Bonnie K Arendt1, Denise K Walters1, Xiaosheng Wu1

  • 1Department of Immunology, Division of Hematology, Mayo Clinic, College of Medicine, Rochester, MN.

Oncotarget
|July 13, 2014
PubMed

Insights

Multiple myeloma cells release microvesicles (MVs) that promote cancer growth. These MVs are rich in CD147, a molecule crucial for stimulating malignant plasma cell proliferation.

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Multiple myeloma (MM) involves malignant plasma cell proliferation in bone marrow.
  • Tumor-derived microvesicles (MVs) are known to alter cellular microenvironments.
  • The role of MVs in MM progression requires further investigation.

Purpose of the Study:

  • To determine if MM cells release MVs.
  • To characterize the biological activity of MM-derived MVs.
  • To investigate the role of CD147 in MV-mediated MM cell growth.

Main Methods:

  • Isolation and characterization of MVs from patient MM cells and human MM cell lines (HMCLs).
  • Assessment of MV-induced proliferation in HMCLs.
  • Utilizing CD147-GFP fusion constructs to track MV-derived CD147 binding and internalization.

Main Results:

  • MM cells and HMCLs release MVs that stimulate MM cell proliferation.
  • MM-derived MVs are enriched with biologically active CD147.
  • Internalization of MV-derived CD147 correlates with increased HMCL proliferation.
  • Downregulation of CD147 in MVs attenuated their proliferative effect on HMCLs.

Conclusions:

  • MV shedding is significant in malignant plasma cell proliferation.
  • MV-mediated intercellular communication plays a key role in MM.
  • MV-enriched CD147 is a critical factor in promoting MM cell proliferation.

Related Concept Videos